CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Oral and intravenous iron therapy differentially alter the on- and off-tumor microbiota in anemic colorectal cancer patients
Authors
Austin G Acheson
Hafid Omar Al-Hassi
+8 more
Andrew D Beggs
Matthew J Brookes
Edward A Dickson
Aditi Kumar
Oliver Phipps
Mohammed Nabil Quraishi
Jonathan Segal
Helen Steed
Publication date
12 March 2021
Publisher
'MDPI AG'
Doi
Cite
Abstract
© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/cancers13061341Iron deficiency anemia is a common complication of colorectal cancer and may require iron therapy. Oral iron can increase the iron available to gut bacteria and may alter the colonic microbiota. We performed an intervention study to compare oral and intravenous iron therapy on the colonic tumor-associated (on-tumor) and paired non-tumor-associated adjacent (off-tumor) microbiota. Anemic patients with colorectal adenocarcinoma received either oral ferrous sulphate (n = 16) or intravenous ferric carboxymaltose (n = 24). On- and off-tumor biopsies were obtained post-surgery and microbial profiling was performed using 16S ribosomal RNA analysis. Off-tumor α- and β-diversity were significantly different between iron treatment groups. No differences in on-tumor diversity were observed. Off-tumor microbiota of oral iron-treated patients showed higher abundances of the orders Clostridiales, Cytophagales, and Anaeroplasmatales compared to intravenous iron-treated patients. The on-tumor microbiota was enriched with the orders Lactobacillales and Alteromonadales in the oral and intravenous iron groups, respectively. The on- and off-tumor microbiota associated with intravenous iron-treated patients infers increased abundances of enzymes involved in iron sequestration and anti-inflammatory/oncogenic metabolite production, compared to oral iron-treated patients. Collectively, this suggests that intravenous iron may be a more appropriate therapy to limit adverse microbial outcomes compared to oral iron.The Ferinject™ used in the original IVICA trial was donated to all study centers, except Nottingham University Hospitals NHS Trust, by Vifor Pharma (Glattbrugg, Switzerland). The study represents independent research funded by the National Institute for Health Research (NIHR) Research for Patient Benefit (RfPB) program (grant number PB-PG-0110-21041)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Heart of England: HEFT Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:www.repository.uhblibrary....
Last time updated on 17/04/2021
Wolverhampton Intellectual Repository and E-theses
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:wlv.openrepository.com:243...
Last time updated on 12/04/2021
HEFT Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:www.repository.uhblibrary....
Last time updated on 21/04/2021
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:openaire_cri...
Last time updated on 01/06/2021
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:publications...
Last time updated on 04/01/2022